SCHEMBL3588408

SCHEMBL3588408

CN1CC(=O)Nc2c(N)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 7/20 0.42
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
DDB1 Q16531 5/20 0.35
ADRA2C P18825 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
BRD4 O60885 2/20 0.34
CREBBP Q92793 1/20 0.34
NPC1 O15118 1/20 0.33
CYP3A4 P08684 1/20 0.33
GRM5 P41594 1/20 0.33
RAB9A P51151 1/20 0.33
GRM1 Q13255 1/20 0.33
FTO Q9C0B1 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
TNF P01375 2/20 0.33
IL1B P01584 2/20 0.33
IKZF1 Q13422 2/20 0.33
IKZF3 Q9UKT9 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31170846 0.81 CRBN (0.44) CRBNCYP11B1CYP11B2DDB1KMT2A
SCHEMBL3588406 0.80 CRBN (0.42) CRBNCYP11B1CYP11B2DDB1KMT2A
SCHEMBL3593120 0.73 CRBN (0.42) CRBNCYP11B1CYP11B2DDB1KMT2A
SCHEMBL2629391 0.72 EPHX2 (0.54) CRBNCYP11B1CYP11B2KMT2AMEN1
SCHEMBL3587267 0.71 BRD4 (0.54) CRBNDDB1KMT2AMEN1BRD4
SCHEMBL3606359 0.70 PDK2 (0.36) CRBNDDB1ADRA2CKMT2AMEN1
SCHEMBL9025184 0.69 CASP3 (0.46) CRBNCYP11B1CYP11B2KMT2AMEN1
SCHEMBL1716064 0.68 SLC6A2 (0.38) CRBNDDB1ADRA2CKMT2AMEN1
SCHEMBL3600186 0.67 CA9 (0.47) CRBNCYP11B1CYP11B2DDB1KMT2A
SCHEMBL3588988 0.67 CYP11B1 (0.53) CRBNCYP11B1CYP11B2DDB1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 CRBN 762/4885CYP11B1 162/4885CYP11B2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.